[go: up one dir, main page]

NO20032801L - Tiazolderivater for behandling av PPAR-relaterte forstyrrelser - Google Patents

Tiazolderivater for behandling av PPAR-relaterte forstyrrelser

Info

Publication number
NO20032801L
NO20032801L NO20032801A NO20032801A NO20032801L NO 20032801 L NO20032801 L NO 20032801L NO 20032801 A NO20032801 A NO 20032801A NO 20032801 A NO20032801 A NO 20032801A NO 20032801 L NO20032801 L NO 20032801L
Authority
NO
Norway
Prior art keywords
ppar
treatment
related disorders
thiazole derivatives
thiazole
Prior art date
Application number
NO20032801A
Other languages
English (en)
Other versions
NO20032801D0 (no
Inventor
Rodolfo Cadilla
Iii Millard Hurst Lambert
Romain Luc Marie Gosmini
Michael Lawrence Sierra
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20032801D0 publication Critical patent/NO20032801D0/no
Publication of NO20032801L publication Critical patent/NO20032801L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel (I). Disse forbindelser anvendes for behandling av PPAR-relaterte sykdommer.
NO20032801A 2000-12-20 2003-06-19 Tiazolderivater for behandling av PPAR-relaterte forstyrrelser NO20032801L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders

Publications (2)

Publication Number Publication Date
NO20032801D0 NO20032801D0 (no) 2003-06-19
NO20032801L true NO20032801L (no) 2003-08-04

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032801A NO20032801L (no) 2000-12-20 2003-06-19 Tiazolderivater for behandling av PPAR-relaterte forstyrrelser

Country Status (27)

Country Link
EP (1) EP1343773B1 (no)
JP (1) JP4209681B2 (no)
KR (1) KR100815022B1 (no)
CN (1) CN1252057C (no)
AR (1) AR035522A1 (no)
AT (1) ATE344253T1 (no)
AU (1) AU2002246713B2 (no)
BR (1) BR0116370A (no)
CA (1) CA2432188A1 (no)
CY (1) CY1105915T1 (no)
CZ (1) CZ20031737A3 (no)
DE (1) DE60124302T2 (no)
DK (1) DK1343773T3 (no)
ES (1) ES2274914T3 (no)
GB (1) GB0031107D0 (no)
HU (1) HUP0400837A3 (no)
IL (2) IL156436A0 (no)
MX (1) MXPA03005699A (no)
MY (1) MY136685A (no)
NO (1) NO20032801L (no)
NZ (1) NZ526543A (no)
PL (1) PL365797A1 (no)
PT (1) PT1343773E (no)
SI (1) SI1343773T1 (no)
TW (1) TWI292759B (no)
WO (1) WO2002062774A1 (no)
ZA (1) ZA200304679B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HUP0302397A3 (en) 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
HUP0401160A3 (en) * 2001-08-13 2008-01-28 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivatives having antiinflammatory activity, process for their preparation and pharmaceutical compositions containing them
ES2316736T3 (es) 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
EP1636198A1 (en) * 2003-06-06 2006-03-22 F. Hoffmann-La Roche Ag Aniline derivatives
RU2344135C2 (ru) 2003-07-02 2009-01-20 Ф.Хоффманн-Ля Рош Аг Тиазолзамещенные индолилпроизводные и их применение в качестве модуляторов ppar
PT1667964E (pt) 2003-09-19 2009-09-02 Janssen Pharmaceutica Nv Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7816367B2 (en) * 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
RU2371437C2 (ru) * 2004-12-31 2009-10-27 Сеул Нэшнл Юниверсити Индастри Фаундейшн Селенорганические соединения и их применение
CA2599281C (en) 2005-02-25 2012-01-17 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
KR100797798B1 (ko) * 2005-02-25 2008-01-24 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 유도체및 그의 제조방법
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
ES2386734T3 (es) 2005-12-22 2012-08-28 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-DELTA
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CA2669639A1 (en) 2006-12-02 2008-06-05 Seoul National University Industry Foundation Aryl compounds as ppar ligands and their use
EP2104666A4 (en) 2007-01-08 2011-05-25 Seoul Nat Univ Ind Foundation THIAZOL COMPOUND (AS PPAR DELTA LIGAND), AND PHARMACEUTICAL, COSMETIC AND HEALTHY FOOD THEREOF
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
MX2010009654A (es) 2008-03-06 2010-09-28 Amgen Inc Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
CA2739888C (en) 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
AU2002246713B2 (en) 2004-09-09
MXPA03005699A (es) 2003-10-06
CZ20031737A3 (cs) 2003-10-15
CY1105915T1 (el) 2011-04-06
AR035522A1 (es) 2004-06-02
HUP0400837A2 (hu) 2004-08-30
NO20032801D0 (no) 2003-06-19
PL365797A1 (en) 2005-01-10
ES2274914T3 (es) 2007-06-01
SI1343773T1 (sl) 2007-04-30
TWI292759B (en) 2008-01-21
CN1527822A (zh) 2004-09-08
HK1059925A1 (en) 2004-07-23
KR100815022B1 (ko) 2008-03-18
NZ526543A (en) 2004-11-26
DE60124302D1 (de) 2006-12-14
DE60124302T2 (de) 2007-05-03
HUP0400837A3 (en) 2007-11-28
JP4209681B2 (ja) 2009-01-14
ATE344253T1 (de) 2006-11-15
DK1343773T3 (da) 2007-02-05
JP2004518702A (ja) 2004-06-24
EP1343773B1 (en) 2006-11-02
GB0031107D0 (en) 2001-01-31
CN1252057C (zh) 2006-04-19
IL156436A (en) 2008-06-05
PT1343773E (pt) 2007-02-28
ZA200304679B (en) 2004-10-04
MY136685A (en) 2008-11-28
KR20030072571A (ko) 2003-09-15
WO2002062774A1 (en) 2002-08-15
EP1343773A1 (en) 2003-09-17
CA2432188A1 (en) 2002-08-15
BR0116370A (pt) 2003-12-09
IL156436A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20031443L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
IT1311922B1 (it) Composti farmaceutici.
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
ATE440603T1 (de) 8-hydroxychinolinderivate
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
GB0111523D0 (en) Chemical compounds
NO960393L (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
DE60009511D1 (de) Nematizide trifluorbutene
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
NO20072060L (no) 2-acylaminotiazolderivater
SE0101082D0 (sv) Novel use
NO20062629L (no) Oksazolderivater av tetrackliner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application